文本分析asco会议1.pptxVIP

Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3 randomized, placebo-controlled trial (ExteNET) ;Background;Neratinib;Study Design;Study Evolution;Study Evolution;Statistical Plan;Results: Patient Tumor Characteristics;Results: Patient Tumor Characteristics;Primary Endpoint: Invasive DFS (ITT);Primary Endpoint: Invasive DFS (ITT);Invasive Disease-free Events;Secondary Endpoints: DFS-DCIS;iDFS by Hormone Receptor;Pre-specified Sub-populations;Safety (Adverse Events ≥10%);Safety (Adverse Events of Special Inter